Business Standard

Gennova to use mRNA tech to develop vaccines for Zika, tuberculosis

mRNA vaccines typically have stringent temperature requirements to remain stable

Vials, Vaccine
Premium

The mRNA vaccine candidate contains a short, synthetic version encoding the spike protein (antigen) of the novel coronavirus Sars-CoV-2.

Sohini Das Mumbai
Gennova Biopharmaceuticals, a subsidiary of Pune-headquartered Emcure Pharmaceuticals, is not only developing India’s first indigenous messenger ribonucleic acid (mRNA) Cov­id-19 vaccine, but also plans to leverage the platform to develop vaccines for the Zika virus, herpes zoster (shingles), and tuberculosis (TB).
 
“The mRNA platform is disease-agnostic. We had started work on this a few years back when we collaborated with Seattle-based HDT Biotech Corporation for developing a therapeutic vaccine for cancer (human papillomavirus-induced cervical cancer in women),” said Samit Mehta, pres­ident and chief operating officer, Gennova. He added that the company planned to use the platform to make vaccines

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in